Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy

ABSTRACT

Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.

KEYWORDS:

• Clinical trials
• CTLA-4 blockade
• immune checkpoint blockade
• next generation immunotherapy
• radiation therapy

Disclosure statement

All authors are employees of Agenus Inc. No other potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.